P781 Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING study
نویسندگان
چکیده
Abstract Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. The long-term, Phase 3b/4 RIVETING study (NCT03281304) assessed efficacy and safety tofacitinib dose reduction from 10 mg twice daily (BID) maintenance therapy to 5 BID in patients (pts) stable remission.1 We present a final analysis after ≥30 months treatment. Methods was double-blind, randomised, parallel-group with 42-month (M) duration. Eligible pts had received ≥2 consecutive years open-label, long-term extension (NCT01470612), been remission ≥6 corticosteroid-free ≥4 weeks prior baseline. primary endpoint at M6 based on modified Mayo (mMayo) score (endoscopic stool frequency subscores ≤1 rectal bleeding subscore 0).1 terminated (primary objective met) when all passed M30 (or discontinued); some already completed visits up M42. Here, we assess throughout. Results Overall, 140 were randomised (1:1) or BID; 50.0% 62.9% mMayo groups, respectively, consistent findings observed other secondary endpoints (Table 1). At M30, differences between generally greater subgroup baseline endoscopic 1 vs 0 without tumour necrosis factor (TNFi) failure percentage who experienced loss by as estimated Kaplan-Meier curves, numerically higher group (28.1%; 95% confidence interval [CI], 17.68–39.49 21.7%; CI, 12.21–32.95, respectively). Table 2 shows adverse events special interest, group. One death occurred due fatal coronavirus disease 2019 pneumonia (10 BID). Conclusion These data showed that most maintained through BID. Dose difference M6.1 Differences groups subgroups TNFi failure. tofacitinib’s known profile; incidence serious infections herpes zoster 1. Vermeire S et al. J Crohns Colitis 2021;15:1130-41.
منابع مشابه
The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis.
Allergic rhinitis is one of the most common chronic disorders in children. It is also one of the most common causes of absence from school. This study reports on the efficacy and safety of a twice-daily oral dose of fexofenadine HCl 30 mg in Asian children aged 6-11 years diagnosed with seasonal or perennial allergic rhinitis. A total of 100 children with a history of allergic rhinitis for more...
متن کاملComparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis
This network meta-analysis aimed to investigate the effectiveness and safety of 100 mg BID and 200 mg QD oral celecoxib in the treatment of OA of the knee or hip. PubMed, Embase and Cochrane Library were searched through from inception to August 2014. Bayesian network meta-analysis was used to combine direct and indirect evidences on treatment effectiveness and safety. A total of 24 RCTs coveri...
متن کاملEffects of adding 5 mg meperidine to 10 mg bupivacaine for spinal anesthesia on postoperative pain in cesarean section surgery
Introduction: Meperidine has the advantages of being widely available and inexpensive. It would be highly cost-benefit if it is used at doses that are without any side-effect. Thus, this study aimed to assess the effect of meperidine 5 mg as an additive to bupivacaine for spinal anesthesia on postoperative pain in cesarean section surgery. Methods: This double-blind randomized clinical trial w...
متن کاملMifepristone 5 mg versus 10 mg for emergency contraception: double-blind randomized clinical trial
PURPOSE To estimate the efficacy and safety of 5 mg and 10 mg mifepristone for emergency contraception up to 144 hours after unprotected coitus. METHODS This double-blind randomized clinical trial was carried out at Eusebio Hernandez Hospital (Havana, Cuba). A total of 2,418 women who requested emergency contraception after unprotected coitus received either 5 mg or 10 mg mifepristone. The va...
متن کامل48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
Background Wk 24 TRANxITION study data showed patients transitioned from immediate release nevirapine (NVP IR) twice daily (BID) to NVP extended release (NVP XR) once-daily (QD) demonstrated non-inferior efficacy to patients continuing on IR NVP BID [1]. Similar safety was reported for NVP XR and NVP IR in the VERxVE study [2]. Wk 48 efficacy/safety data from TRANxITION study are presented here.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Crohn's and Colitis
سال: 2023
ISSN: ['1876-4479', '1873-9946']
DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0911